When hiPSCs were differentiated into cardiomyocytes (hiPSC-CMs) and injected into the hearts of rodents or pigs after experimentally induced myocardial infarction (MI), the treatment was associated with significant improvements in cardiac function 4 weeks later. However, only a small 
T he proliferative capacity of cardiomyocytes in the adult mammalian heart is limited, 1 and the small number of cardiac stem/progenitor cells that are present in the heart is not capable of regenerating the amount of myocardium that is lost to ischemia or other myocardial injuries; [2] [3] [4] [5] [6] thus, researchers have investigated several strategies for enhancing myocardial repair by delivering exogenous cells to the injured myocardium. [7] [8] [9] [10] [11] In a 1994 pilot study, fetal cardiomyocytes were stably engrafted for up to 2 months after injection into the hearts of mice, 12 and subsequent studies demonstrated that transplanted autologous skeletal myoblasts improved function in cryoinfarcted rabbit hearts. 13 Many other cell types, or combinations of cell types, have been investigated (eg, cardiosphere-derived cells, bone marrow mononuclear cells, mesenchymal stem cells, adipose-derived cells, endothelial progenitor cells, and pluripotent stem cell-derived cardiomyocytes), but human induced pluripotent stem cells (hiPSCs) are among the most promising sources of cells for therapeutic applications because they can be generated from a patient's own somatic cells and potentially be used to produce an unlimited number and variety of cells that may be readministered to the patient.
proportion (often just a few percent or less) of transplanted cells are retained and survive at the site of administration, regardless of the type of cell administered or whether the study was performed in animal models or the clinical setting. [14] [15] [16] We hypothesized if the transplanted cells can be induced to proliferate, then even a small initial population of engrafted cardiomyocytes may eventually grow and replace a substantial amount of the scar tissue in the infarcted region with functional cardiac tissue. Notably, the G1-to-S phase transition of the cell cycle is regulated by cyclin D proteins, and the expression of CCND2 (cyclin D2) seems to preserve cardiac function in mice by restoring at least a portion of the myocardial mass that is lost to MI or cautery injury. 1, [17] [18] [19] Therefore, in the present study, we investigated whether using the hiPSC-CMs from a novel hiPSC cell line with overexpressing CCND2 can lead to significantly larger size of graft and result in better improvement in left ventricular (LV) chamber function.
Methods
All experimental protocols were approved by The Institutional Animal Care and Use Committee of the University of Alabama at Birmingham and performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (publication No. 85-23). Data were presented as mean±SEM and each in vitro experiment was performed for at least 3×. Significance (P<0.05) was determined via the Student t test for comparisons between 2 groups and via 2-way ANOVA for comparisons between 3 or more groups. Detailed methods on hiPSC culture and differentiation, qRT-PCR (quantitative reverse transcription polymerase chain reaction), animal model of acute MI and cell transplantation, cell cycle evaluation, and statistical analysis are provided in the Online Data Supplement.
Generation of CCND2-Overexpressing hiPSCs
CCND2 (Addgene No. 8958) was amplified via PCR with 2 oligos (forward: 5′ AGAGCCACCGGTATGGAGCTGCTGTGCCACGAGGT 3′, reverse: 5′ CTGCAGGCGCGCCGAATTTTTTTTTTAAGTTT CACCCT 3′; Invitrogen); then, the amplified product was extracted from a 2% agrose gel, digested, and subcloned into a lenti-α-MHC (myosin heavy chain) plasmid (Addgene No. 21230) by using Ascl and Age I endonucleases (Online Figure IA through ID) . Gene insertion was confirmed by Sanger sequencing and by electrophoresis with a 1% agarose gel; then, the lenti-α-MHC/CCND2 plasmid was cotransfected with packaging plasmids pCMV-VSV-G, pRSV-Rev, and pMDLg/ pRRE (Addgene plasmids) into HEK293 cells. The cells were cultured for 48 hours, and the virus-containing supernatants were collected and mixed with Lenti-XConcentrator, stored overnight at 4°C, and centrifuged at 3000 rpm and 4°C for 10 minutes to pellet the cell debris; then, the supernatants were filtered through a 0.45 µm low protein binding membrane (Millipore) and used immediately for hiPSC transduction.
The hiPSCs carried a luciferase and GFP (green fluorescent protein) reporter gene 7, 20, 21 and were expanded on Matrigel-coated dishes for 4 days; then, the cells were treated with G418 (400 µg/mL) for 36 hours, rinsed twice with deionized PBS, and allowed to recover in culture for 2 to 3 days with daily medium changes. After the recovery period, the G418 treatment and rinsing steps were repeated, and the cells were allowed to recover in culture until the colonies reached sufficient size and cell density for passage; then, individual colonies (clones) were harvested, and expanded in culture as described previously, 22, 23 and the expression of CCND2 in hiPSC-CMs was evaluated via Western blot. Two clones of CCND2-overexpressing hiPSCs were selected for differentiation.
Engraftment Rate
Because the hiPSCs carried a luciferin reporter gene and were of human origin, engraftment was determined both via in vivo bioluminescence imaging (BLI) and by histological assessments of cells that expressed the hcTnT (human variant of cardiac troponin T) and human nuclear antigen. BLI was performed at the University of Alabama, Birmingham, Small Animal Imaging Shared Facility with a Xenogen IVIS-100 system. Briefly, a standard curve was generated from BLI measurements of known quantities (0.5×10 
Novelty and Significance
What Is Known?
• The myocardium lost because of ischemic injury is replaced by an infarct scar of fibrous tissue.
• Infarct size is linearly related to the severity of left ventricular dysfunction and dilatation, which eventually lead to heart failure.
• The effectiveness of cell-based therapies for myocardial repair is limited by a low engraftment rate.
What New Information Does This Article Contribute?
• Overexpression of CCND2 (cyclin D2) promotes sustained cell cycle activity in cultured human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs).
• CCND2-expressing hiPSC-CMs exhibit superior myocardial regenerative potential by enhancing myocyte proliferation compared with their nonexpressing counterparts after transplantation into infarcted hearts.
• CCND2-mediated cell cycle activity is sufficient to increase the engraft size in recipient hearts, which contribute to a significantly better left ventricular chamber function.
Transplanted hiPSC-CMs is limited by poor rates of engraftment.
In this study, we show that overexpression of a cell cycle protein, CCND2, enhances cell cycle of hiPSC-CMs. The grafted iPSC-CMs exhibit the capacity to undergo CCND2 mediated myocytes proliferation, reduce infarction size, and improve cardiac function. Future preclinical studies are warranted using large animal models to examine if myocytes proliferation mediated remuscularization can ultimately replace the left ventricular scar, and whether larger grafts may increase the arrhythmogenicity. , and 5×10
5
) of hiPSC-CMs that had been digested and plated in 6-well plates; then, mice were anesthetized with isoflurane and intraperitoneally injected with D-luciferin (375 mg/kg body weight). Ten minutes later, after the luciferin had traveled to the heart and been converted to the optically active species (oxyluciferin), 24 the number of engrafted cells was determined by comparing BLI signal intensity in the front left chest region to the standard curve. 8 Histological assessments of the engraftment rate were performed as described previously. 25 Cells that expressed both hcTnT and human nuclear antigen were counted in every 10th serial section of the whole heart and the total was multiplied by 10 to obtain the number of engrafted hiPSC-CMs per heart. The engraftment rate was calculated by dividing the total number of engrafted hiPSC-CMs by the number of injected cells ( 3×10 5 ) and expressed as a %.
Cell Cycle Activation

Cultured Cells
Four weeks after initiation of cardiomyocyte differentiation, 5-Bromo-2'-deoxy-uridine (bromodeoxyuridine [Brdu], 15 µmol/L final concentration) was added to the culture medium for 12 hours; then, the cells were fixed with ethanol at −20°C for 15 minutes, and Brdu staining was performed with a Brdu Labeling and Detection Kit (Roche life science, Inc; Cat No. 11296736001) as directed by the manufacturer's instructions. The expression of other cell cycle markers (Ki67, phosphorylated histone 3, and Aurora-B) was evaluated with the corresponding antibodies (Online Table II ) in ethanol-fixed cells that had been counterstained for the expression of hcTnT and human Nkx2.5 to confirm hiPSC-CM identity. The number of nuclei that stained positively for each marker was counted, normalized to the total number of hiPSC-CMs (ie, the number of hcTnT/Nkx2.5 double-positive cells), and expressed as a %.
Transplanted Cells
Animals were intraperitoneally injected with Brdu (5 mg/d) for 2 consecutive days; then, the animals were euthanized and hearts were fixed for 4 hours with 4% paraformaldehyde and overnight with 30% sucrose. The hearts were cut into transverse sections (10 μm thickness) with a cryostat, and then the sections were stained with antiBrdu, anti-Ki67, and antiphosphorylated histone 3 antibodies and counterstained with antihuman Nkx2.5 and anti-hcTnT antibodies. The number of nuclei that stained positively for each marker was counted in at least 5 sections per heart, normalized to the total number of hiPSC-CMs, and expressed as a %.
Results
CCND2 Overexpression Activates the Cell Cycle and Increases Proliferation in Cultured hiPSC-CMs
Immunofluorescence analyses indicated that the proportion of cells that expressed markers for proliferation (Ki67 26, 27 ; Figure 1A ) for phase S (Brdu 26, 28 ; Figure 1B ) and phase M (phosphorylated histone 3 17, 27 ; Figure 1C ) of the cell cycle and for cytokinesis (Aurora B 29, 30 ; Figure 1D ) was significantly greater in CCND2-overexpressing hiPSC-CMs (hiPSC-CCND2 OE CMs) than in hiPSC-CMs with normal levels of CCND2 (hiPSC-CCND2 WT CMs). However, CCND2 overexpression did not seem to change the proportion of cells that were undergoing apoptosis ( Figure 1E ). The proportion of cells in S phase declined over a prolonged, 24-week culture period but remained significantly greater among hiPSC-CCND2 OE CMs than among hiPSC-CCND2 WT CMs (Figure 1Fi) , and the majority (≈80% or more) of the cells in both populations contained just 1 nucleus at 4 weeks (Online Figure IVA) and 24 weeks (Online Figure IVB) after differentiation, which is consistent with the proportion of mononuclear cardiomyocytes in postnatal human hearts (≈78%). 31, 32 Furthermore, although cells that have exited the cell cycle typically have shorter telomeres, 33 a substantial amount of telomerase activity was observed in hiPSC-CCND2 WT CMs after 1 week of differentiation, perhaps because some of the cells remained undifferentiated. Nevertheless, telomerase activity was significantly higher in hiPSC-CCND2 OE CMs than in hiPSC-CCND2 WT CMs throughout the culture period (Figure 1Fii and 1Fiii) . Western blot and densitometry quantification indicated that CCND2 expression was gradually reduced in hiPSC-CCND2 WT CMs, whereas it is stably remained in hiPSC-CCND2 OE CMs during the 24-week culture period (Online Figure VA) .
It was reported that CCND2 activates catalytic CDK (cyclin-dependent kinases 4 and CDK6), which leads to a subsequent phosphorylation of Rb (retinoblastoma protein). 34 The phosphorylation of Rb results in the dissociation of Rb/E2F1, and the release of E2F1 is required to induce cell cycle progression. 35 Initial characterization of hiPSC-CCND2 OE CMs revealed that overexpression of CCND2 increased the level of CDK4 and CDK6 (Online Figure IIIC) . To elucidate the mechanisms of CCND2-mediated cell cycle of activity in hiPSC-CMs, we checked expression of the downstream molecules of CCND2 and other molecules that are known to regulate cardiomyocyte cell cycle. At 4 weeks after differentiation (which is the time point we collected cells for transplantation), overexpression of CCND2 inhibited the activity of p53 and Rb via promoting its phosphorylation and enhanced the activity of E2F1 and c-Myc via promoting their expression (Online Figure VB) .
CCND2 Overexpression Increases the Potency of Transplanted hiPSC-CMs for Treatment of MI in Mice
To determine whether the effect of CCND2 overexpression on cell cycle progression in cultured hiPSC-CMs may increase the cells' potency for myocardial recovery, cardiac functional parameters were evaluated in mice that had been treated with hiPSC-CCND2 in the front wall of the LV; one of the injection sites was located in the infarcted region and the other 2 were at the border of the infarct. A third group of animals (the MI group) was treated with equivalent injections of cell-free PBS after MI injury, and animals in the Sham group underwent all surgical procedures for MI induction except for the ligation step.
Echocardiographic measurements of LV ejection fraction (Figure 2A ) indicated that heart function was equally (and severely) compromised in animals from the hiPSC-CCND2 OE CM, hiPSC-CCND2 WT CM, and MI groups at week 1 after MI induction, but by week 4, measurements were significantly greater in both cell treatment groups than in MI animals and in the hiPSC-CCND2 OE CM group than in hiPSC-CCND2 WT CM animals. Furthermore, histological assessments performed in a subset of mice that were euthanized at week 1 indicated that the infarcted regions occupied ≈22% to 23% of the LV in animals from all 3 groups that underwent ligation, but by week 4, infarct sizes in both of the cell treatment groups had declined substantially and were significantly smaller than in MI animals ( Figure 2B and 2C); measurements were also significantly smaller in hiPSC-CCND2 OE CM animals than in the hiPSC-CCND2 WT CM group. Assessments of both the heart-weight :body-weight ratio ( Figure 2D ) and of the cardiomyocyte minimal fiber diameter ( Figure 2E ) were also similar in hiPSC-CCND2 OE CM, hiPSC-CCND2 WT CM, and MI groups at week 1 but significantly smaller in both groups of cell-treated animals than in the MI group and in hiPSC-CCND2 OE CM animals than in hiPSC-CCND2 WT CM animals, at week 4. Collectively, these observations demonstrate that the potency of transplanted hiPSC-CMs for restoring heart function, for regenerating lost myocardial tissue, and for limiting myocardial hypertrophy after MI injury in mice increases significantly when the cells are engineered to overexpress CCND2.
CCND2 Overexpression Increases the Number of Engrafted hiPSC-CMs After Transplantation into Infarcted Mouse Hearts
One of the primary barriers to the effectiveness of myocardial cell therapy is the exceptionally low engraftment rate; thus, we investigated whether the significant benefits associated with CCND2 overexpression in transplanted hiPSC-CMs were accompanied by an increase in the number of engrafted cells. Because the transplanted cells carried a luciferase reporter plasmid and were of human origin, engraftment was evaluated via BLI ( Figure 3A through 3E) and by identifying cells that coexpressed the hcTnT and human nuclear antigen (Figure 3Fi ). Both assessments indicated that the engraftment rates in the 2 cell treatment groups were similar at week 1 but significantly higher in hiPSC-CCND2 OE CM animals than in the 
hiPSC-CCND2
WT CM group at week 4 ( Figure 3Fii) . Although 96% to 98% of the transplanted cells were cardiomyocytes (Online Figure IIIB) , the CM and non-CM populations may proliferate at different rates, which (because the non-CMs also express luciferase) could confound the results from our BLI measurements. Thus, we determined the proportion of human nuclear antigen positive cells that did or did not coexpress hcTnT (ie, hiPSC-derived CMs or non-CMs, respectively) at WT CMs) are present in infarcted mouse hearts at week 4 after transplantation. The transplanted cells carried a luciferase reporter plasmid and were of human origin; thus, engraftment was evaluated via (A through E) bioluminescence imaging (BLI) and (F and G) by identifying cells that expressed the human variant of cardiac troponin T (hcTnT) and human nuclear antigen (HNA). A, A standard curve was generated from BLI measurements of known quantities of human induced pluripotent stem cells (hiPSC-CMs). B, One and 4 wk after myocardial infarction (MI) induction and treatment with intramyocardial injections of hiPSC-CCND2 OE CMs (CCND2 OE ) or hiPSC-CCND2 WT CMs (CCND2 WT ), the mice were injected with luciferin, and BLI images were collected 10 min later. C, BLI signal intensity was compared with the standard curve to determine (D) the number of engrafted cells; then, (E) the engraftment rate was calculated by dividing the number of engrafted cells by the total number of cells administered and expressed as a %. *P<0.05 vs Sham, #P<0.05 vs PBS, +P<0.05 vs CCND2
WT . F, i, Heart sections from mice that had been euthanized 1 and 4 wk after MI induction and treatment with hiPSC-CCND2
WT CMs or hiPSC-CCND2 OE CMs were stained for the presence of hcTnT and HNA; nuclei were counterstained with DAPI (4',6-diamidino-2-phenylindole; 10× images: bar=100 µm, 40× images: bar=20 µm). ii, The engraftment rate was calculated by dividing the number of cells that expressed both hcTnT and HNA by the total number of cells administered and expressed as a %. *P<0.05 vs CCND2
WT . iii, Sections were stained with wheat germ agglutinin (WGA) to define the cell border and with antibodies against HNA and hcTnT; then, the proportion of HNA-positive cells that also coexpressed hcTnT was determined and expressed as a %. C through E, SHAM (n=8), PBS (n=10), CCND2
WT (n=10), and CCND2 OE (n=10) at week 1; SHAM (n=8), PBS (n=9), CCND2
WT (n=9), and CCND2 OE (n=9) at week 4. G and H, n=5 animals per treatment group at week 1 and 4; 32 to 40 sections per animal were evaluated, and 1 to 8 high power of fields per section were assessed. week 4 after cell transplantation; our results confirm that in both hiPSC-CCND2 OE CM-and hiPSC-CCND2 WT CM-treated hearts, ≈96% of the engrafted hiPSC-derived cells were cardiomyocytes (Figure 3Fiii ). Furthermore, both the absolute number and proportion of transplanted hiPSC-CCND2 OE CMs that remained at the site of administration increased between the 2 time points, and the proportion of transplanted cells that incorporated Brdu ( Figure 4A ) and expressed Ki67 ( Figure 4B ) or phosphorylated histone 3 ( Figure 4C ), but not the proportion of apoptotic hiPSC-CMs ( Figure 4D ), was significantly greater in hiPSC-CCND2 OE CM animals than in the hiPSC-CCND2 WT CM group at week 4. Thus, the improved engraftment appeared to evolve via an increase in proliferation rather than survival. Brdu incorporation by native cardiomyocytes did not differ significantly between animals in the hiPSC-CCND2 OE CM and hiPSC-CCND2 WT CM treatment groups at either time points (Online Figure VIA) , but apoptotic native cardiomyocytes were significantly less common at week 1 (Online Figure VIB) , and cells that expressed the endothelial marker CD31 were significantly greater at week 4 (Online Figure VIC) , in both cell treatment groups than in MI animals, which suggests that the transplanted hiPSC-CMs activated paracrine mechanisms that protected native cells from the early onset of programmed cell death 36, 37 and amplified the angiogenic response 7 to MI injury.
Discussion
One of the primary barriers to limit the effectiveness of cardiac cell therapy is the low engraftment rate a few weeks after administration. Here, we show that CCND2 overexpression activates cell cycle progression in hiPSC-MHC-CMs and, consequently, that even a small number of grafted hiPSC-CCND2 OE CMs can proliferate continuously, thereby increase the graft size, which in turn results in remarkable reduction of infarct size and improving LV function.
Pulse-chase studies by Zhang et al 38 indicated that when hiPSC-CMs were isolated from early (10-20 day) contracting embryoid bodies, 11% to 15% of the cells incorporated Brdu compared with just 1% of hiPSC-CMs obtained from late (day 60) embryoid bodies. Furthermore, the prevalence of Ki67 expression in differentiating hiPSC-CMs decreases from ≈22% on day 10 to nearly 0% on day 110, 39 and transplanted hiP-SC-CMs have been shown to withdraw from the cell cycle. 39 These observations are consistent with our analyses of hiPSC-CCND2 WT CMs; however, CCND2 overexpression not only increased Brdu incorporation by >3.5-fold after 1 week of cell culture but also the proportion of hiPSC-CCND2 OE CMs that continued to incorporate Brdu over the ensuing 20 weeks ( Figure 1F ). Brdu incorporation also increased more than 10-fold over 3 weeks in engrafted hiPSC-CCND2 OE CMs but remained essentially unchanged in engrafted cells with normal levels of CCND2. Thus, CCND2 overexpression seems to increase both the number of proliferative hiPSC-CMs and the length of time that they remain proliferative. The results from assessments of long-term engraftment rates in transplanted hiPSC-CMs have been somewhat inconsistent. Funakoshi et al 39 have reported that the number of engrafted hiPSC-CMs increased during the first 2 months after transplantation, whereas the engraftment rate appeared to decline in studies by Ong et al. 8 Both investigations were performed in mice; however, engraftment was evaluated via luciferase activity which, because luciferin is typically administered via intraperitoneal injection and its conversion to the optically active species (oxyluciferin) requires ATP and oxygen, 40 may be confounded by even small differences in the amount of blood flow at the site of cell administration. Thus, we corroborated the results from our in vivo luciferase measurements by evaluating the number of transplanted cells that were present in histological sections from the hearts of mice at week 1 and week 4 after injury. The results from both assessments indicate that the number of engrafted hiPSC-CCND2 OE CMs, but not hiPSC-CCND2 WT CMs, increased substantially between the 2 time points and likely contributed to the concomitant improvements in cardiac function, infarct size, and hypertrophy.
Study Limitations
Because the duration of our in vivo experiments was limited to 4 weeks, the long-term fate of transplanted hiPSC-CCND2 OE CMs remains unknown; however, telomerase activity declined over 24 weeks in cultured cells, which suggests that the cells' telomeres shorten gradually over time and, consequently, the transplanted cells will eventually withdraw from the cell cycle and become less proliferative. Future studies are warranted to examine whether a significant remuscularization of hearts with MI could result in an increased arrhythmogenicity using large animal models.
Conclusions
We demonstrate for the first time that 4 weeks after acute MI, a significant remuscularization of an injured LV can be achieved by a novel hiPSC line with MHC-promoter driven CCND2 overexpression in hiPSC-CMs. The higher engraftment rate observed in hiPSC-CCND2 OE CM-treated hearts can also lead to a corresponding increase in the activation of paracrine mechanisms, such as the increase in angiogenesis. This increase in paracrine activity may also contribute to the improvements in LV remodeling and LV chamber function. Thus, the hiPSC-CCND2 OE CMs result in significantly larger graft size and increased angiogenesis at border zone 4 weeks after the transplantation, which are accompanied by a significant reduction of infarct size and improvement in LV chamber function.
